Publication

Article

BioPharm International

BioPharm International-10-04-2010
Volume2010 Supplement
Issue 8

BioPharm International, October 2010 Supplement (PDF)

The Evolution of Vaccines

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue
BioPharm International, October 2010 Supplement (PDF)
table2_t-690799-1408639063847.gif
Release and Stability Testing Programs for a Novel Virus-Like Particle Vaccine
table2_t-690800-1408639059498.gif
Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNs
onraedt-fig1_t-690798-1408639069152.jpg
Sterilizing Filtration of Adjuvanted Vaccines: Ensuring Successful Filter Qualification
table2_t-690797-1408639073293.gif
An Alternative Platform for Rapid Production of Effective Subunit Vaccines

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
PRAGUE, CZECHIA - NOVEMBER 1, 2019: Astellas logo in front of their main office for Prague. Astellas Pharma is a Japanese Pharmaceutical company spread worldwide | Image Credit: © Jerome - stock.adobe.com
August 23rd 2025

Astellas and Pfizer Bladder Cancer Therapy Recommended by UK’s NICE

Patrick Lavery
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
August 23rd 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Bio/Pharma's Response to Tariff and Trade Policy
August 23rd 2025

Bio/Pharma's Response to Tariff and Trade Policy: Survey Results

Christopher Cole
Mastering Antibody-Drug Conjugates
August 23rd 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
The front of the REGENXBIO facility in Rockville, Montgomery County, Maryland. REGENXBIO is a biotechnology company researching Adeno-Associate Virus (AAV) gene therapy | Image Credit: © MJ Kerr - stock.adobe.com
August 23rd 2025

FDA Extends Review Period for REGENXBIO Hunter Syndrome Treatment

Patrick Lavery
Lung cancer, 3D illustration and photo under microscope. Histopathology light micrograph of small cell lung cancer | Image Credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com
August 23rd 2025

Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer

Feliza Mirasol
© 2025 MJH Life Sciences

All rights reserved.